Athens Research & Technology是成立于2010年的新興生物高科技制品公司，該公司擁有BSL-2實驗室及超過11000平方英尺的cGMP生產(chǎn)廠房，并且通過ISO 9001：2008認證。Athens公司致力于純化分離高純度，高活性的人類蛋白質(zhì)及研發(fā)多克隆抗血清產(chǎn)品。提供包括高純度及活性的絲氨酸蛋白酶，蛋白酶抑制劑，中性粒細胞酶，載脂蛋白，脂蛋白，血小板蛋白，轉(zhuǎn)鐵蛋白，免疫球蛋白等等。公司產(chǎn)品適用于炎癥，冠狀動脈疾病，自身免疫性疾病，癌癥，阿爾茨海默氏病等眾多研究領域，已被世界*制藥公司及診斷試劑公司用于體外診斷試劑盒/免疫檢測試劑盒、藥物篩選、細胞培養(yǎng)液（包括干細胞）等產(chǎn)品研發(fā)。除了人類蛋白質(zhì)，我們還從動物血清和組織中分離多種蛋白質(zhì)及酶類。此外，Athens Research and Technology還提供特殊試劑/蛋白定制服務，以滿足研究人員的不同需求。

athensresearch 16-14-051200說明書——上海起發(fā)

Elastase, Human Neutrophil

MW：29500

消光系數(shù)：0.985

無鹽凍干固體。

重組：離心后，我們建議將50mM醋酸鈉（pH 5.5）和150mM NaCl加入到原始體積中，然后輕輕混合以確保充分均質(zhì)。

儲存：<=-20°C

這種酶降解彈性蛋白、膠原蛋白和蛋白多糖，并與肺動脈塞和類風濕性關節(jié)炎的發(fā)展有關。

參考：Baugh，R.J.和Travis，J.1976。生物化學15,836;Bode，W.等人，1986年。EMBO J.5（10），2453

活性：每毫克蛋白質(zhì)20-22個單位。一個單位被定義為在25攝氏度、pH 7.5下每分鐘水解一摩爾MeO-Suc-Ala-Ala-Pro-Val-pNA的酶的量。

純度：SDS-PAGE顯示>=95%

由經(jīng)美國食品藥品監(jiān)督管理局要求的檢測顯示對HBsAg、抗-HCV、抗-HBc無反應且抗-HIV 1和2呈陰性的全血制備。

雅典研究與技術公司的產(chǎn)品是實驗室試劑，不得用于人體或任何藥物用途

Kerros C, et al.
Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells.
J Biol Chem. 2017 Jun 16;292(24):10295-10305. doi: 10.1074/jbc.M116.773051. Epub 2017 May 3.

Martin KR, Kantari-Mimoun C, Yin M, Pederzoli-Ribeil M, et al.
Proteinase 3 Is a Phosphatidylserine-binding Protein That Affects the Production and Function of Microvesicles.
J Biol Chem. 2016 May 13;291(20):10476-89. doi: 10.1074/jbc.M115.698639. Epub 2016 Mar 9.

Edwards JV, Fontenot KR, Prevost NT, Pircher N, Liebner F, Condon BD.
Preparation, Characterization and Activity of a Peptide-Cellulosic Aerogel Protease Sensor from Cotton.
Sensors (Basel). 2016 Oct 26;16(11). pii: E1789.

Chawla A, Alatrash G, Philips AV, Qiao N, et al.
Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.
Cancer Immunol Immunother. 2016 Jun;65(6):741-51. doi: 10.1007/s00262-016-1841-6. Epub 2016 Apr 29.

Sinden NJ, et al.
α-1-Antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.
Am J Physiol Lung Cell Mol Physiol. 2015 Jan 15;308(2):L179-90.

Ksiazek M, et al.
Miropin, a Novel Bacterial Serpin from the Periodontopathogen Tannerella forsythia, Inhibits a Broad Range of Proteases by Using Different Peptide Bonds within the Reactive Center Loop.
J Biol Chem. 2015 Jan 2;290(1):658-70. doi: 10.1074/jbc.M114.601716. Epub 2014 Nov 11.

Ramadass M, Ghebrehiwet B, Kew RR.
Enhanced recognition of plasma proteins in a non-native state by complement C3b. A possible clearance mechanism for damaged proteins in blood.
Mol Immunol. 2015 Mar;64(1):55-62. doi: 10.1016/j.molimm.2014.10.022. Epub 2014 Nov 15.

Thomas MP, et al.
Leukocyte Protease Binding to Nucleic Acids Promotes Nuclear Localization and Cleavage of Nucleic Acid Binding Proteins.
J Immunol. 2014 Jun 1;192(11):5390-7. doi: 10.4049/jimmunol.1303296. Epub 2014 Apr 25.

Ungurs MJ, Sinden NJ, Stockley RA.
Progranulin is a substrate for neutrophil-elastase and proteinase-3 in the airway and its concentration correlates with mediators of airway inflammation in COPD
Am J Physiol Lung Cell Mol Physiol. 2014 Jan 1;306(1):L80-7. doi: 10.1152/ajplung.00221.2013. Epub 2013 Nov 1.

Sinden NJ, Koura F, Stockley RA.
The significance of the F variant of alpha-1-antitrypsin and unique case report of a PiFF homozygote.
BMC Pulm Med. 2014 Aug 7;14:132. doi: 10.1186/1471-2466-14-132.

Kenninston JA, et al.
Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody.
J Biol Chem. 2014 Aug 22;289(34):23596-608. doi: 10.1074/jbc.M114.569061. Epub 2014 Jun 26.

Tejera P, et al.
Functional Characterization of Polymorphisms in the Peptidase Inhibitor 3 (Elafin) Gene and Validation of Their Contribution to Risk of Acute Respiratory Distress Syndrome.
Am J Respir Cell Mol Biol. 2014 Aug;51(2):262-72. doi: 10.1165/rcmb.2013-0238OC.

Zheng K, et al.
Influence of glycosylation pattern on the molecular properties of monoclonal antibodies.
MAbs. 2014 May-Jun;6(3):649-58. doi: 10.4161/mabs.28588. Epub 2014 Mar 24.